Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is a promising digital therapeutics company with a strong focus on delivering user experiences, longer sustained engagement, and stronger clinical outcomes at affordable prices, which translates to the highest return on investment in the industry. The company has a solid track record of growth, with a 30% reduction in adjusted operating losses expected in 2026 and cash flow breakeven by mid-2027. While there are risks associated with the high demand for HCIT and potential customer losses, DarioHealth's pipeline and current access to covered lives position them well for success in the enterprise market.

Bears say

DarioHealth is seeing strong growth on the B2B2C side, with 10 new accounts added in 1Q26 and a pipeline expansion to $127M. However, the company's target of breakeven by mid-'27 may be overly ambitious in light of potential changes in materiality of factors within the ESG space, as well as increasing competition in the DTx market. The company may need to reassess its strategy and focus on sustainable growth rather than short-term financial goals.

DarioHealth (DRIO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 2 analysts, DarioHealth (DRIO) has a Buy consensus rating as of May 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.